Anti-Tal1 (phospho S122) antibody (ab138646)
Key features and details
- Rabbit polyclonal to Tal1 (phospho S122)
- Suitable for: WB
- Reacts with: Human
- Isotype: IgG
Overview
-
Product name
Anti-Tal1 (phospho S122) antibody
See all Tal1 primary antibodies -
Description
Rabbit polyclonal to Tal1 (phospho S122) -
Host species
Rabbit -
Specificity
ab138646 detects endogenous levels of Tal1 only when phosphorylated at S122 -
Tested applications
Suitable for: WBmore details -
Species reactivity
Reacts with: Human
Predicted to work with: Mouse -
Immunogen
Synthesized phospho-peptide derived from the internal region of Human Tal1 around the phosphorylation site of S122.
-
Positive control
- Extracts from Jurkat cells treated with PMA.
-
General notes
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at -20°C. -
Storage buffer
pH: 7.40
Preservative: 0.02% Sodium azide
Constituents: 49% PBS, 50% Glycerol (glycerin, glycerine), 0.88% Sodium chloride
PBS is without Mg2+ and Ca2+ -
Concentration information loading...
-
Purity
Immunogen affinity purified -
Purification notes
ab138646 was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation. -
Clonality
Polyclonal -
Isotype
IgG -
Research areas
Associated products
-
Compatible Secondaries
-
Isotype control
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab138646 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB |
1/500 - 1/1000. Predicted molecular weight: 34 kDa.
|
Notes |
---|
WB
1/500 - 1/1000. Predicted molecular weight: 34 kDa. |
Target
-
Function
Implicated in the genesis of hemopoietic malignancies. It may play an important role in hemopoietic differentiation. Serves as a positive regulator of erythroid differentiation. -
Tissue specificity
Leukemic stem cell. -
Involvement in disease
Note=A chromosomal aberration involving TAL1 may be a cause of some T-cell acute lymphoblastic leukemias (T-ALL). Translocation t(1;14)(p32;q11) with T-cell receptor alpha chain (TCRA) genes. -
Sequence similarities
Contains 1 basic helix-loop-helix (bHLH) domain. -
Domain
The helix-loop-helix domain is necessary and sufficient for the interaction with DRG1. -
Post-translational
modificationsPhosphorylated on serine residues. Phosphorylation of Ser-122 is strongly stimulated by hypoxia.
Ubiquitinated; subsequent to hypoxia-dependent phosphorylation of Ser-122, ubiquitination targets the protein for rapid degradation via the ubiquitin system. This process may be characteristic for microvascular endothelial cells, since it could not be observed in large vessel endothelial cells. -
Cellular localization
Nucleus. - Information by UniProt
-
Database links
- Entrez Gene: 6886 Human
- Entrez Gene: 21349 Mouse
- Omim: 187040 Human
- SwissProt: P17542 Human
- SwissProt: P22091 Mouse
- Unigene: 705618 Human
- Unigene: 439685 Mouse
-
Alternative names
- bHLHa17 antibody
- Class A basic helix-loop-helix protein 17 antibody
- OTTHUMP00000009563 antibody
see all
Images
Datasheets and documents
-
SDS download
-
Datasheet download
References (1)
ab138646 has been referenced in 1 publication.
- Godavarthy PS et al. The vascular bone marrow niche influences outcome in chronic myeloid leukemia via the E-selectin - SCL/TAL1 - CD44 axis. Haematologica 105:136-147 (2020). PubMed: 31018977